Tamsulosin is used to treat Benign Prostatic Hyperplasia (BPH), prescribed annually to about 12.6 million patients worldwide. It is an alpha-adrenergic antagonist that reduces the tone of the prostate smooth muscle involved in the pathophysiology of BPH. By acting on alpha 1A receptors, predominant in the prostate, tamsulosin also acts on receptors present in the brain. This study consisted of a literature review aimed at disseminating scientific knowledge about the relationship between the use of tamsulosin and the onset of dementia. Pubmed, Scopus, Scielo, Embase, and Web of Science studies involving dementia in patients using tamsulosin in the last five years were selected. The review showed a risk correlation and a higher incidence of dementia in treated patients. The risk ratio, when compared to other medicines, approached 1.20. In conclusion, it was identified the need for clinical trials with higher sampling power to increase relational significance due to the high prevalence of BPH and the extensive use of tamsulosin in elderly patients with the disease.
Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016 Aug;43(3):289-97. doi: 10.1016/j.ucl.2016.04.001.
Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016 May 5;2:16031. doi: 10.1038/nrdp.2016.31.
Ulrich S. Differential prescription behavior in benign prostatic syndrome may explain relationship found between tamsulosin and dementia. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1157-1158. doi: 10.1002/pds.4666.
Frankel JK, Duan Y, Albertsen PC. Is Tamsulosin Linked to Dementia in the Elderly? Curr Urol Rep. 2018 Jul 3;19(9):69. doi: 10.1007/s11934-018-0821-0.
Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, Palacios JM, Vasylyev A, Manyak MJ. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015 Sep;116(3):450-9. doi: 10.1111/bju.13033.
Gill SS, Bai AD. Beta testing the potential link between the alpha antagonist tamsulosin and dementia. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):349-350. doi: 10.1002/pds.4382.
Madersbacher S, Michel MC. Re: Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic Hyperplasia. Eur Urol. 2018 Oct;74(4):522-523. doi: 10.1016/j.eururo.2018.07.013.
Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L, Prokofyeva A,Loparev S. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male. 2018 Jun;21(2):121-129. doi: 10.1080/13685538.2017.1398723.
Nikolic K, Filipic S, Smoliński A, Kaliszan R, Agbaba D. Partial least square and hierarchical clustering in ADMET modeling: prediction of blood-brain barrier permeation of α-adrenergic and imidazoline receptor ligands. J Pharm Pharm Sci. 2013;16(4):622-47.
Duan Y, Grady JJ, Albertsen PC, Helen Wu Z. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):340-348. doi: 10.1002/pds.4361.
Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience. 2007 Apr 25;146(1):471-80.
This work is licensed under a Creative Commons Attribution 4.0 International License.